ArticleAlimentary pharmacology & therapeutics2026
A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost. Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
- A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study.Alimentary pharmacology & therapeutics · 2026Article
- Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAn advanced therapy care pathway (ACP) for the treatment of patients with IBD can reduce practice variation and improve outcomes.
aimsThis study aimed to estimate the effect of the ACP on costs and quality of life, and to assess the cost-effectiveness of the ACP.
methodsA cost-utility and cost-effectiveness analysis was conducted from a societal perspective. The ACP was implemented in six hospitals, and two hospitals in the same region served as controls. Costs and quality of life were assessed during a baseline period (December 2020-December 2021) and an intervention period after implementing the ACP (March 2022-March 2023). Quality-adjusted life years (QALYs) were derived from the EQ-5D-5L; disease control from the IBD-Control questionnaire. A difference-in-differences (DiD) analysis was conducted, and the net monetary benefit and incremental cost-effectiveness ratio (ICER) were calculated.
resultsIn total, 1,173 patients were included (intervention n = 841, control n = 332). Baseline costs per patient were €23,259.96 in the intervention hospitals and €22,837.93 in the control hospitals. During the intervention period, costs decreased to €20,959.76 in intervention hospitals. This reduction was not observed in control hospitals (€22,191.21). The DiD-analysis showed cost savings of -€1933.69; QALYs (0.001) and disease control (0.15) did not change. The ICER indicated cost savings without compromising quality of life or disease control.
conclusionsThe implementation of an ACP for the treatment of patients with IBD reduces costs, maintains quality of life and disease control, and is cost-effective. These results emphasise that the implementation of care pathways in current practices should be considered. TRIAL REGISTRATION NUMBER: NL-OMON21751. Website: Value-based healthcare for Inflammatory Bowel Disease: Improving (cost-) effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.